Clinical trials: Eosinophilic Gastroenteritis
Eosinophilic Esophagitis
Antihistamines in Eosinophilic Esophagitis
Researchers are assessing the safety and effectiveness of antihistamines in the treatment of eosinophilic esophagitis.
- Trial name
- ATEE (NCT04248712)
- Testing
- Famotidine, Loratadine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Eosinophilic Esophagitis
Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)
The purpose of this study is to conduct a clinical trial of two formulations of budesonide (nebulized/swallowed versus viscous/swallowed) in patients with EoE to determine if medication contact time and distribution in the…
- Trial name
- NCT00961233
- Testing
- inhaled/swallowed budesonide, viscous/swallowed budesonide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
Eosinophilic Esophagitis, Connective Tissue Disorders
Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
The purpose of this research study is to test the safety of losartan potassium and see what effects (good and bad) it has on you and your eosinophilic esophagitis.
- Trial name
- NCT01808196
- Testing
- Losartan Potassium
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for up to 26 doses.
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
- Trial name
- NCT03664960
- Testing
- AK002
- Where
- 17 sites in United States
- Volunteers
- 58 people
- Sponsor
- Allakos Inc.
Eosinophilic Esophagitis
Eosinophilic Esophagitis Clinical Therapy Comparison Trial
Eosinophilic Esophagitis (EoE) is a disorder in which a type of white blood cell (eosinophil) involved in allergic reactions, enter and cover the walls of the esophagus (food pipe).
- Trial name
- NCT01821898
- Testing
- Oral Budesonide, Elimination diet
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Dupilumab in Eosinophilic Gastritis
40 participants with Eosinophilic Gastritis 12-70 years of age will be randomly assigned with dupilumab or placebo subcutaneous injections every two weeks for a total of 12 weeks.
- Trial name
- NCT03678545
- Testing
- Dupilumab (blinded)
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses.
- Trial name
- ENIGMA (NCT03496571)
- Testing
- AK002
- Where
- 21 sites in United States
- Volunteers
- 65 people
- Sponsor
- Allakos Inc.
Eosinophilic Esophagitis
A Study of Flovent in Patients With Eosinophilic Esophagitis
The purpose of this study is to test the effects (both good and bad) of high dose swallowed fluticasone propionate (Flovent) in subjects with eosinophilic esophagitis (EoE).
- Trial name
- NCT00426283
- Testing
- Flovent
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Marc Rothenberg, MD
Eosinophilic Gastritis, Eosinophilic Duodenitis
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002), given monthly for 6 doses, in patients with moderately to severely active Eosinophilic…
- Trial name
- ENIGMA 2 (NCT04322604)
- Testing
- lirentelimab (AK002)
- Where
- 60 sites in United States
- Volunteers
- 181 people
- Sponsor
- Allakos Inc.
Eosinophilic Esophagitis
Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)
The purpose of our research study is to assess whether patients with EoE who have achieved control of their disease on topical Fluticasone or Budesonide are able to cycle or take breaks from their treatment with continued…
- Trial name
- NCT05444543
- Testing
- Fluticasone Propionate, Budesonide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University Hospitals Cleveland Medical Center
Respiratory System Agents, Anti-Asthmatic Agents
Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Background: Eosinophils are white blood cells that help fight infections. High eosinophil levels can damage people s organs, causing hypereosinophilic syndrome (HES).
- Conditions
- Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders
- Trial name
- HESIL5R (NCT02130882)
- Testing
- benralizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Eosinophilic Esophagitis
Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)
This is a prospective single center clinical trial of allergen-specific immune signature-guided dietary elimination therapy to assess the clinical effectiveness of this technique.
- Trial name
- IDiET (NCT02722148)
- Testing
- Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Eosinophilic Esophagitis
Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
The purpose of this study is to assess the clinical efficacy of proton pump inhibitors in comparison to aerosolized swallowed steroids for the treatment of eosinophilic esophagitis (EE).
- Trial name
- NCT00895817
- Testing
- Swallowed fluticasone, Esomeprazole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Walter Reed Army Medical Center
Eosinophilic Esophagitis
An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)
The purpose of this study is to test the safety and effectiveness of Losartan potassium in subjects with eosinophilic esophagitis (EoE) including those with a connective tissue disorder (CTD) and those without a CTD.
- Trial name
- NCT03029091
- Testing
- Losartan Potassium
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
The primary aim of this study was to determine the proportion of patients with esophageal eosinophilic infiltration that have objective (measurable) evidence of gastroesophageal reflux disease (GERD).
- Conditions
- Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
- Trial name
- NCT00728481
- Testing
- Esomeprazole, Budesonide
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Mayo Clinic
Oesophagitis, Eosinophilic
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.
- Trial name
- NCT00358449
- Testing
- mepolizumab
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Esophagitis
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
Eosinophilic esophagitis (EE) is an increasingly recognized condition characterized by dysphagia, food impaction or other obstructive esophageal symptoms in children and young adults.
- Trial name
- NCT00123630
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Eosinophilic Esophagitis
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434).
- Trial name
- NCT00635089
- Testing
- reslizumab
- Where
- 36 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Ception Therapeutics
Eosinophilic Esophagitis
Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms, which medication provides a more durable treatment…
- Trial name
- NCT02019758
- Testing
- Oral Viscous Budesonide, Fluticasone MDI
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- University of North Carolina, Chapel Hill
Eosinophilic Esophagitis
Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)
Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal symptoms.
- Trial name
- FLUTE (NCT03191864)
- Testing
- APT-1011
- Where
- 75 sites in United States, Belgium and 4 more
- Volunteers
- 106 people
- Sponsor
- Adare Pharmaceuticals, Inc.